Dyno Therapeutics is reshaping the gene therapy landscape with AI-powered AAV vectors

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • Eric Kelsic
  • Alan Crane
  • Sam Simai
  • Adrian Veres
  • George Church
  • Tomas Bjorklund

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • Catch @ekelsic and @samsinai at the Synthetic Biology-Based Therapeutics Summit! https://t.co/dXxctvoscv #AAV… https://t.co/iLgwFQXlVj@Dyno_Tx - 02:50 PM Dec 7th
  • Join @Dyno_Tx at the 3rd Gene Therapy for Neurological Disorders. We're looking forward to an interesting discussio… https://t.co/kV5nqyt3Zm@Dyno_Tx - 12:39 PM Dec 7th
  • Dyno's engineering efforts are helping the scientific community scale their exploration through @argoproj and… https://t.co/CUkcWcl3HB@Dyno_Tx - 08:13 PM Dec 6th